Online inquiry

IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8531MR)

This product GTTS-WQ8531MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD4 gene. The antibody can be applied in AIDS research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000616.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 920
UniProt ID P01730
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8531MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13283MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ12793MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ1476MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ12606MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ280MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ8405MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HS006
GTTS-WQ7891MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GSK-249320
GTTS-WQ13713MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RC48
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW